Corporate Profile's CPReports.com Publishes Report by RAY DIRKS of RAY DIRKS Research on Oramed Pharmaceuticals
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 10/04/11 -- Corporate Profile's financial website announces Ray Dirks' report on Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) (OTCQB: ORMP).
To view report: or
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Oramed's technology is based on over 25 years of research performed by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is based in Jerusalem.
For more information:
CPReports.com features Gene Marcial, Ray Dirks and Rob Goldman. The website and newsletter provide readers and subscribers fresh, original, and highly informative ideas and market commentary that they won't get anywhere else. Content is focused on what is going on in the stock market and on Wall Street.
where Fashion meets Finance, merging two mainstream industries results in the unique platform for today's and market info.
Ray Dirks came to Wall Street with Goldman, Sachs & Co. in 1963 where he was established as the leading insurance stock analyst dealing with institutional investors and high-net worth investors both in the U.S. and internationally. Ray's research includes Healthcare Stocks and Special Situations. Ray has written two books, "The Great Wall Street Scandal" and "Heads You Win, Tails You Win," published by McGraw-Hill and Bantam Books respectively. Ray can be reached at:
Safe Harbor Disclaimer
Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectation.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.10.2011 - 05:00 Uhr
Sprache: Deutsch
News-ID 1042089
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Healthcare
Anmerkungen:
Diese Pressemitteilung wurde bisher 121 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Corporate Profile's CPReports.com Publishes Report by RAY DIRKS of RAY DIRKS Research on Oramed Pharmaceuticals
"
steht unter der journalistisch-redaktionellen Verantwortung von
Corporate Profile LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
